{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:19:59Z","timestamp":1773116399586,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40744-024-00718-6","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T14:03:45Z","timestamp":1728569025000},"page":"1591-1609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Development and Content Validation of the Sj\u00f6gren\u2019s Related Quality of Life Instrument (SRQoL)"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-5865","authenticated-orcid":false,"given":"Jessica","family":"Marvel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Gargon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Howse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishwarya","family":"Chohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Mayhew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayle","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monia","family":"Steenackers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Perella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pushpendra","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"issue":"4","key":"718_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/acr.21591","volume":"64","author":"S Shiboski","year":"2012","unstructured":"Shiboski S, Shiboski C, Criswell L, et al. ACR classification criteria for Sj\u00f6gren\u2019s syndrome: a data-driven, expert consensus approach in the Sj\u00f6gren\u2019s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64(4):475\u201387.","journal-title":"Arthritis Care Res"},{"key":"718_CR2","first-page":"247","volume":"6","author":"R Patel","year":"2014","unstructured":"Patel R, Shahane A. The epidemiology of Sj\u00f6gren\u2019s syndrome. Clin Epidemiol. 2014;6:247.","journal-title":"Clin Epidemiol"},{"issue":"4","key":"718_CR3","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.rdc.2008.08.010","volume":"34","author":"SJ Bowman","year":"2008","unstructured":"Bowman SJ. Patient-reported outcomes including fatigue in primary Sj\u00f6gren\u2019s syndrome. Rheum Dis Clin N Am. 2008;34(4):949\u201362.","journal-title":"Rheum Dis Clin N Am"},{"issue":"20","key":"718_CR4","first-page":"354","volume":"114","author":"A-L Stefanski","year":"2017","unstructured":"Stefanski A-L, Tomiak C, Pleyer U, Dietrich T, Burmester GR, D\u00f6rner T. The diagnosis and treatment of Sj\u00f6gren\u2019s syndrome. Deutsches arzteblatt Int. 2017;114(20):354.","journal-title":"Deutsches arzteblatt Int"},{"issue":"2","key":"718_CR5","volume":"3","author":"KM Hammitt","year":"2017","unstructured":"Hammitt KM, Naegeli AN, van den Broek RW, Birt JA. Patient burden of Sj\u00f6gren\u2019s: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity. Rheum Musculoskelet Dis Open. 2017;3(2):e000443.","journal-title":"Rheum Musculoskelet Dis Open"},{"issue":"6","key":"718_CR6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/ard.2010.143743","volume":"70","author":"R Seror","year":"2011","unstructured":"Seror R, Ravaud P, Mariette X, et al. EULAR Sj\u00f6gren\u2019s syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis. 2011;70(6):968\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"718_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2013-204615","volume":"74","author":"R Seror","year":"2015","unstructured":"Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. 2015;74(5):859\u201366.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"718_CR8","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/acr.21991","volume":"65","author":"R Seror","year":"2013","unstructured":"Seror R, Gottenberg J, Devauchelle-Pensec V, et al. EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI) and EULAR Sj\u00f6gren\u2019s syndrome patient-reported index (ESSPRI): a complete picture of primary Sj\u00f6gren\u2019s syndrome patients. Arthritis Care Res. 2013;65(8):1358\u201364.","journal-title":"Arthritis Care Res"},{"key":"718_CR9","unstructured":"Ndife B, Fenel S, Lewis S, Agashivala N. Development of a symptom diary for use in patients with Sjogren\u2019s syndrome [abstract]. Arthritis Rheumatol. 2021;73."},{"issue":"7","key":"718_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","volume":"81","author":"R Seror","year":"2022","unstructured":"Seror R, Baron G, Camus M, et al. Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis. 2022;81(7):979\u201389.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"718_CR11","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","volume":"3","author":"S Arends","year":"2021","unstructured":"Arends S, de Wolff L, van Nimwegen JF, et al. Composite of relevant endpoints for Sj\u00f6gren\u2019s syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol. 2021;3(8):e553\u201362.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"718_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2014-206418","volume":"75","author":"P Brito-Zeron","year":"2016","unstructured":"Brito-Zeron P, Kostov B, Solans R, et al. Systemic activity and mortality in primary Sj\u00f6gren syndrome: predicting survival using the EULAR-SS disease activity index (ESSDAI) in 1045 patients. Ann Rheum Dis. 2016;75(2):348\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"718_CR13","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/acr.22974","volume":"69","author":"D Cornec","year":"2017","unstructured":"Cornec D, Devauchelle-Pensec V, Mariette X, et al. Severe health-related quality of life impairment in active primary Sj\u00f6gren\u2019s syndrome and patient-reported outcomes: data from a large therapeutic trial. Arthritis Care Res. 2017;69(4):528\u201335.","journal-title":"Arthritis Care Res"},{"issue":"8","key":"718_CR14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/annrheumdis-2011-200460","volume":"71","author":"P Meiners","year":"2012","unstructured":"Meiners P, Arends S, Brouwer E, Spijkervet F, Vissink A, Bootsma H. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sj\u00f6gren\u2019s syndrome treated with rituximab. Ann Rheum Dis. 2012;71(8):1297\u2013302.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"718_CR15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/annrheumdis-2013-203736","volume":"73","author":"RV Moerman","year":"2014","unstructured":"Moerman RV, Arends S, Meiners PM, et al. EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis. 2014;73(2):472\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"718_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","volume":"52","author":"L Quartuccio","year":"2013","unstructured":"Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sj\u00f6gren\u2019s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology. 2013;52(2):276\u201381.","journal-title":"Rheumatology"},{"issue":"2","key":"718_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","volume":"75","author":"R Seror","year":"2016","unstructured":"Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sj\u00f6gren\u2019s syndrome with EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"718_CR18","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","volume":"2","author":"EHM van der Heijden","year":"2020","unstructured":"van der Heijden EHM, Blokland SLM, Hillen MR, et al. Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. Lancet Rheumatol. 2020;2(5):e260\u20139.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"718_CR19","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s40744-022-00489-y","volume":"9","author":"N Griffiths","year":"2022","unstructured":"Griffiths N, Wratten S, Flynn J, et al. Content validity of Sj\u00f6gren\u2019s syndrome symptom diary and functional assessment of chronic illness therapy-fatigue in patients with Sj\u00f6gren\u2019s. Rheumatol Ther. 2022;9(6):1559\u201374.","journal-title":"Rheumatol Ther"},{"issue":"12","key":"718_CR20","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1136\/annrheumdis-2016-210758","volume":"76","author":"H Tsuboi","year":"2017","unstructured":"Tsuboi H, Hagiwara S, Asashima H, et al. Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sj\u00f6gren\u2019s syndrome with other sets of criteria in Japanese patients. Ann Rheum Dis. 2017;76(12):1980\u20135.","journal-title":"Ann Rheum Dis"},{"key":"718_CR21","doi-asserted-by":"crossref","unstructured":"Li L, Cui Y, Chen S, Zhao Q, Gu Z. AB0513 Fatigue in Chinese patients with primary Sj\u00f6gren\u2019s syndrome: a cross sectional study. Br Med J. 2017.","DOI":"10.1136\/annrheumdis-2017-eular.3076"},{"issue":"3","key":"718_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.2014.7682","volume":"312","author":"J-E Gottenberg","year":"2014","unstructured":"Gottenberg J-E, Ravaud P, Pu\u00e9chal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312(3):249\u201358.","journal-title":"JAMA"},{"issue":"4","key":"718_CR23","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/art.20146","volume":"50","author":"X Mariette","year":"2004","unstructured":"Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sj\u00f6gren\u2019s syndrome: results of the randomized, controlled trial of remicade in primary Sj\u00f6gren\u2019s syndrome (TRIPSS). Arthritis Rheumatol. 2004;50(4):1270\u20136.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"718_CR24","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1093\/rheumatology\/key370","volume":"60","author":"ST Miyamoto","year":"2021","unstructured":"Miyamoto ST, Valim V, Fisher BA. Health-related quality of life and costs in Sj\u00f6gren\u2019s syndrome. Rheumatology. 2021;60(6):2588\u2013601.","journal-title":"Rheumatology"},{"issue":"3","key":"718_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40744-023-00531-7","volume":"10","author":"C Perella","year":"2023","unstructured":"Perella C, Steenackers M, Robbins B, et al. Patient experience of Sj\u00f6gren\u2019s disease and its multifaceted impact on patients\u2019 lives. Rheumatol Ther. 2023;10(3):601\u201314.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"718_CR26","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.55563\/clinexprheumatol\/vsv60z","volume":"39","author":"C Seghieri","year":"2021","unstructured":"Seghieri C, Lupi E, Tzioufas AG, De Vita S, Baldini C. Patient-reported experience and health-related quality of life in patients with primary Sj\u00f6gren\u2019s syndrome in Europe. Clin Exp Rheumatol. 2021;39(6):S123\u201330.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"718_CR27","doi-asserted-by":"publisher","first-page":"e0172056","DOI":"10.1371\/journal.pone.0172056","volume":"12","author":"A Lackner","year":"2017","unstructured":"Lackner A, Ficjan A, Stradner MH, et al. It\u2019s more than dryness and fatigue: the patient perspective on health-related quality of life in primary Sj\u00f6gren\u2019s syndrome\u2014a qualitative study. PLoS ONE. 2017;12(2):e0172056.","journal-title":"PLoS ONE"},{"issue":"5","key":"718_CR28","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/rheumatology\/keq315","volume":"50","author":"U Kiltz","year":"2011","unstructured":"Kiltz U, van der Heijde D, Cieza A, et al. Developing and validating an index for measuring health in patients with ankylosing spondylitis. Rheumatology. 2011;50(5):894\u20138.","journal-title":"Rheumatology"},{"issue":"3","key":"718_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"issue":"7","key":"718_CR30","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202863","volume":"73","author":"D Lendrem","year":"2014","unstructured":"Lendrem D, Mitchell S, McMeekin P, et al. Health-related utility values of patients with primary Sj\u00f6gren\u2019s syndrome and its predictors. Ann Rheum Dis. 2014;73(7):1362\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6846","key":"718_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","volume":"305","author":"JE Brazier","year":"1992","unstructured":"Brazier JE, Harper R, Jones N, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160\u20134.","journal-title":"BMJ"},{"issue":"1","key":"718_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1741-2358.2002.00053.x","volume":"19","author":"J Rostron","year":"2002","unstructured":"Rostron J, Rogers S, Longman L, Kancy S, Field EA. Health-related quality of life in patients with primary Sj\u00f6gren's syndrome and xerostomia: a comparative study. Gerodontology. 2002;19(1):53\u20139.","journal-title":"Gerodontology"},{"issue":"6","key":"718_CR33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/joim.13451","volume":"291","author":"J Tarn","year":"2022","unstructured":"Tarn J, Lendrem D, McMeekin P, Lendrem C, Hargreaves B, Ng WF. Primary Sj\u00f6gren\u2019s syndrome: longitudinal real-world, observational data on health-related quality of life. J Intern Med. 2022;291(6):849\u201355.","journal-title":"J Intern Med"},{"key":"718_CR34","doi-asserted-by":"crossref","unstructured":"Lackner A, Stradner MH, Hermann J, et al., editors. Assessing health-related quality of life in primary Sj\u00f6gren\u2019s syndrome\u2014the PSS-QoL. Semin Arthritis Rheum. 2018;48(1):105\u2013110.","DOI":"10.1016\/j.semarthrit.2017.11.007"},{"key":"718_CR35","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s11136-011-0003-8","volume":"21","author":"JM Norquist","year":"2012","unstructured":"Norquist JM, Girman C, Fehnel S, DeMuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res. 2012;21:1013\u201320.","journal-title":"Qual Life Res"},{"key":"718_CR36","unstructured":"Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. 2022. https:\/\/www.fda.gov\/media\/131230\/download. Accessed June 2024."},{"issue":"1","key":"718_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, et al. 2016 ACR-EULAR classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"718_CR38","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/acr.23707","volume":"71","author":"PM Izmirlym","year":"2019","unstructured":"Izmirlym PM, Buyon JP, Wan I, et al. The incidence and prevalence of adult primary Sj\u00f6gren\u2019s syndrome in New York county. Arthritis Care Res. 2019;71(7):949\u201360.","journal-title":"Arthritis Care Res"},{"key":"718_CR39","unstructured":"Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. 2018. https:\/\/www.fda.gov\/media\/139088\/download. Accessed June 2024."},{"issue":"10","key":"718_CR40","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ, Johnston M, Robertson C, et al. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25(10):1229\u201345.","journal-title":"Psychol Health"},{"issue":"1","key":"718_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382.","journal-title":"Field Methods"},{"issue":"3","key":"718_CR42","doi-asserted-by":"publisher","first-page":"A33","DOI":"10.1016\/j.jval.2015.03.198","volume":"18","author":"R Lamoureux","year":"2015","unstructured":"Lamoureux R, Shields A, Stokes J, Yaworsky A, Galipeau N. How many subjects are enough for symptom-focused concept elicitation studies? A retrospective analysis of saturation across twenty-six studies. Value Health. 2015;18(3):A33.","journal-title":"Value Health"},{"key":"718_CR43","volume-title":"Cognitive interviewing: a tool for improving questionnaire design","author":"GB Willis","year":"2004","unstructured":"Willis GB. Cognitive interviewing: a tool for improving questionnaire design. London: Sage; 2004."},{"key":"718_CR44","unstructured":"Food and Drug Administration. Patient-focused drug development: Selecting, developing, or modifying fit-for-purpose clinical outcome assessments. 2022. https:\/\/www.fda.gov\/media\/159500\/download. Accessed June 2024."},{"key":"718_CR45","unstructured":"Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf. Accessed June 2024."},{"key":"718_CR46","unstructured":"ATLAS.ti. Scientific software development GmbH [ATLAS.ti 22 Windows]. 2022. https:\/\/atlasti.com."},{"issue":"2","key":"718_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"718_CR48","doi-asserted-by":"crossref","unstructured":"Joffe H, Yardley L. Content and thematic analysis. In: Marks DF, Yardley L, editors. Research methods for clinical and health psychology. SAGE Publications; 2003. pp. 56\u201368.","DOI":"10.4135\/9781849209793.n4"},{"issue":"4","key":"718_CR49","first-page":"373","volume":"79","author":"World Medical Association. World Medical Association Declaration of Helsinki","year":"2001","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Org. 2001;79(4):373.","journal-title":"Bull World Health Org"},{"key":"718_CR50","unstructured":"Food and Drug Administration. Regulations: good clinical practice and clinical trials. 2021. https:\/\/www.fda.gov\/science-research\/clinical-trials-and-human-subject-protection\/regulations-good-clinical-practice-and-clinical-trials. Accessed June 2024."},{"key":"718_CR51","unstructured":"European Medicines Agency. Good clinical practice\u2014scientific guideline. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf. Accessed June 2024."},{"issue":"8","key":"718_CR52","doi-asserted-by":"publisher","first-page":"W-163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","volume":"147","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, Elm EV, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W-163-W\u221294.","journal-title":"Ann Intern Med"},{"issue":"1","key":"718_CR53","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/rheumatology\/kes311","volume":"52","author":"\u00d8 Palm","year":"2013","unstructured":"Palm \u00d8, Garen T, Berge Enger T, et al. Clinical pulmonary involvement in primary Sj\u00f6gren\u2019s syndrome: prevalence, quality of life and mortality\u2014a retrospective study based on registry data. Rheumatology. 2013;52(1):173\u20139.","journal-title":"Rheumatology"},{"key":"718_CR54","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11136-008-9430-6","volume":"18","author":"J Greenhalgh","year":"2009","unstructured":"Greenhalgh J. The applications of PROs in clinical practice: what are they, do they work, and why? Qual Life Res. 2009;18:115\u201323.","journal-title":"Qual Life Res"},{"key":"718_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13293-015-0037-7","volume":"6","author":"JE Brandt","year":"2015","unstructured":"Brandt JE, Priori R, Valesini G, Fairweather D. Sex differences in Sj\u00f6gren\u2019s syndrome: a comprehensive review of immune mechanisms. Biol Sex Differ. 2015;6:1\u201313.","journal-title":"Biol Sex Differ"},{"issue":"4","key":"718_CR56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2036.2004.02091.x","volume":"20","author":"M Reilly","year":"2004","unstructured":"Reilly M, Bracco A, Ricci JF, Santoro J, Stevens T. The validity and accuracy of the work productivity and activity impairment questionnaire\u2013irritable bowel syndrome version (WPAI: IBS). Aliment Pharmacol Ther. 2004;20(4):459\u201367.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00718-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00718-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00718-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T16:02:32Z","timestamp":1731427352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00718-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["718"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00718-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jessica Marvel is an employee of Novartis Services Inc. Monia Steenackers, Chiara Perella, and Pushpendra Goswami are employees and shareholders of Novartis AG. Gayle Kenney was an employee and shareholder of Novartis AG at the time of this research. Elizabeth Gargon, Chloe Howse, Aishwarya Chohan, and Megan Mayhew are employees of Adelphi Values Ltd, a health outcomes agency who were paid by Novartis to conduct the research described in this manuscript. Nicola Williamson was an employee of Adelphi Values at the time of research and is now an employee and shareholder of UCB. Linda Stone has been a patient advocate representing Sj\u00f6gren\u2019s for Novartis and Servier. Benjamin Fisher has undertaken consultancy for Novartis, BMS, Servier, Galapagos, Roche, UCB, Sanofi, Janssen, Otsuka, Amgen, and AstraZeneca, and has received research funding from Janssen, Servier, Galapagos, Celgene, Novartis, and AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval and oversight was provided by Salus Institutional Review Board in the USA and Reading Independent Ethics Committee in the UK. Approval notices (protocol number NO9433A) were received in December 2022. The study was performed and developed in accordance with the Declaration of Helsinki and its later amendments in line with Good Clinical Practice guidelines. All subjects provided informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available to protect participant confidentiality.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}